Results 271 to 280 of about 14,072,748 (310)

Treatment of Chronic Hepatitis B

Current Pharmaceutical Design, 2002
Infection with the hepatitis B virus has switched over the last 20 years from the classical HBeAg positive serologic pattern to a HBeAg negative form that is linked, in the Mediterranean basin, with the epidemiologic replacement of the causative wild-type of virus B with mutant variants, whereby mutations in the core-promoter and in the pre-core region
M, Lagget, M, Rizzetto
openaire   +2 more sources

The management of chronic hepatitis B

The American Journal of Medicine, 1994
The immediate goals of hepatitis B virus (HBV) therapy are to suppress the histologic progression of the disease and diminish infectivity. Although many drugs have been used in the treatment of this condition, only interferon has proven to be consistently effective.
openaire   +2 more sources

Chronic Hepatitis B Infection

Clinics in Liver Disease, 2012
The management of chronic hepatitis B virus (HBV) infection requires understanding the natural history of the disease as well as the risks, benefits, and limitations of the therapeutic options. This article covers the principles governing when to start antiviral therapy, discusses recent advances using hepatitis B surface antigen quantification to ...
Alexander, Kuo, Robert, Gish
openaire   +2 more sources

Treatment of chronic hepatitis B

Journal of Viral Hepatitis, 1994
SUMMARY.Chronic infection with the hepatitis B virus (HBV) is a major cause of worldwide morbidity and mortality. A large number of therapeutic approaches has been tried, including interferon (IFN), nucleoside analogues and immunomodulators. To date controlled clinical trials have shown that only IFN is of long‐term value but many patients fail to ...
openaire   +2 more sources

Economics of chronic hepatitis B and hepatitis C

Journal of Hepatology, 2007
Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years.
Arathi, Rajendra, John B, Wong
openaire   +2 more sources

Coinfection of Chronic Hepatitis B and Fasciolosis

Infection, 2004
Chronic hepatitis B and fasciolosis are associated with the induction of T-cell responses polarized to the Th2 subtype. Interferon-alpha enhances innate immunity as well as Th1 immune response. We present a male patient with chronic hepatitis B and fasciolosis who responded to chronic hepatitis treatment with hepatitis B virus (HBV) vaccine, interferon-
ISLER, M, DEMIRCI, M, Aridogan, Buket, SENOL, A, KORKMAZ, M   +4 more
openaire   +4 more sources

Treatment of Chronic Hepatitis B

Minerva gastroenterologica e dietologica, 2010
Approximately 350-420 million people worldwide are chronically infected with hepatitis B virus (HBV). Chronic hepatitis B can result in liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Reactivation of hepatitis B is possible in patients with inactive or resolved hepatitis B often leading to liver failure.
Lai, CL, Yuen, RMF
openaire   +4 more sources

Pegylated interferons for chronic hepatitis B

Antiviral Research, 2003
Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire   +4 more sources

Lamivudine for chronic hepatitis B

Expert Review of Anti-infective Therapy, 2004
Lamivudine (Epivir, GlaxoSmithKline) was approved by the US Food and Drug Administration for the treatment of adult patients with chronic hepatitis B in 1998, and has since been shown to be of benefit to selected patients with chronic hepatitis B. Drug resistance is the main issue encountered during therapy, with lamivudine resistant mutants emerging ...
openaire   +2 more sources

Chronic Hepatitis B Infection

JAMA, 2018
More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer.Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and ...
Lydia S Y, Tang, Emily, Covert, Eleanor, Wilson, Shyam, Kottilil   +3 more
openaire   +2 more sources